High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

Victoria Heredia-Soto; Andrés Redondo; Alberto Berjón; María Miguel-Martín; Esther Díaz; Roberto Crespo; Alicia Hernandez; Laura Yebenes; Alejandro Gallego; Jaime Feliu; David Hardisson; Marta Mendiola

doi:10.18632/oncotarget.25098

journal article Apr 24, 2018

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

Victoria Heredia-Soto

Andrés Redondo

Alberto Berjón

María Miguel-Martín Esther Díaz Roberto Crespo Alicia Hernandez Laura Yebenes

Alejandro Gallego Jaime Feliu David Hardisson

Marta Mendiola

Oncotarget Vol. 9 No. 31 pp. 21893-21903 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.25098

Topics

No keywords indexed for this article. Browse by subject →

References

45

[1]

Shih "The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded" Am J Pathol (2016) 10.1016/j.ajpath.2015.11.011

[2]

Montell "Ovarian cancer metastasis: integrating insights from disparate model organisms" Nat Rev Cancer (2005) 10.1038/nrc1611

[3]

Johnson "Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions" Exp Cell Biol (1987)

[4]

The basics of epithelial-mesenchymal transition

Raghu Kalluri, Robert A. Weinberg

Journal of Clinical Investigation 2009 10.1172/jci39104

[5]

Reich "Epithelial-mesenchymal transition in ovarian carcinoma" Front Oncol (2012)

[6]

Feilotter "EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer" BMC Cancer (2012) 10.1186/1471-2407-12-91

[7]

Keeney "Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer" J Natl Cancer Inst (2014)

[8]

Goode "Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes" Clin Cancer Res (2017) 10.1158/1078-0432.ccr-17-0246

[9]

Mes-Masson "Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer" BMC Cancer (2012) 10.1186/1471-2407-12-379

[10]

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

Maria Vinci, Sharon Gowan, Frances Boxall et al.

BMC Biology 2012 10.1186/1741-7007-10-29

[11]

Li "An Immunohistochemical Algorithm for Ovarian Carcinoma Typing" Int J Gynecol Pathol (2016) 10.1097/pgp.0000000000000274

[12]

Bowtell "The genesis and evolution of high-grade serous ovarian cancer" Nat Rev Cancer (2010) 10.1038/nrc2946

[13]

Kaye "Rethinking ovarian cancer: recommendations for improving outcomes" Nat Rev Cancer (2011) 10.1038/nrc3144

[14]

The Changing View of High-Grade Serous Ovarian Cancer

Els M.J.J. Berns, David D. Bowtell

Cancer Research 2012 10.1158/0008-5472.can-11-3911

[15]

Schultz "Evaluating cell lines as tumour models by comparison of genomic profiles" Nat Commun (2013) 10.1038/ncomms3126

[16]

Huntsman "Type-specific cell line models for type-specific ovarian cancer research" PLoS One (2013) 10.1371/journal.pone.0072162

[17]

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al.

Nature 2012 10.1038/nature11003

[18]

Clements "Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment" PLoS One (2013) 10.1371/journal.pone.0057056

[19]

Rizzi "Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells" Biomaterials (2010) 10.1016/j.biomaterials.2010.07.064

[20]

Dou "Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures" BMC Cell Biol (2013) 10.1186/1471-2121-14-7

[21]

Lawrenson "A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells" Lab Invest (2013) 10.1038/labinvest.2013.41

[22]

Brown "Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype" Int J Cancer (2009) 10.1002/ijc.24188

[23]

Kisaalita "Microtissue size and hypoxia in HTS with 3D cultures" Drug Discov Today (2012) 10.1016/j.drudis.2012.03.004

[24]

Trotter "Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe" Int J Radiat Oncol Biol Phys (1992) 10.1016/0360-3016(92)90840-e

[25]

Bader "Mass transfer and metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane system" Biomaterials (2007) 10.1016/j.biomaterials.2007.08.033

[26]

Webb "Characterization of a functional C3A liver spheroid model" Toxicol Res (Camb) (2016) 10.1039/c6tx00101g

[27]

Chan "High-Throughput 3D Tumor Spheroid Screening Method for Cancer Drug Discovery Using Celigo Image Cytometry" SLAS Technol (2017) 10.1177/2211068216652846

[28]

Machado-Santelli "The multiple facets of drug resistance: one history, different approaches" J Exp Clin Cancer Res (2014) 10.1186/1756-9966-33-37

[29]

de Jong "Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions" Drug Resist Updat (2016) 10.1016/j.drup.2015.11.005

[30]

Eccles "Tumor spheroid-based migration assays for evaluation of therapeutic agents" Methods Mol Biol (2013) 10.1007/978-1-62703-311-4_16

[31]

Eccles "Two-dimensional vs. three-dimensionaltumor migration and invasion assays" Methods Mol Biol (2013) 10.1007/978-1-62703-311-4_15

[32]

Chan "Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer" Cytometry A (2017) 10.1002/cyto.a.23143

[33]

Kurman "Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis" Mod Pathol (2011) 10.1038/modpathol.2011.85

[34]

Lozano "Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End" Cold Spring Harb Perspect Med (2016) 10.1101/cshperspect.a026211

[35]

Integrated genomic analyses of ovarian carcinoma

Nature 2011 10.1038/nature10166

[36]

Shih "Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications" Int J Gynecol Pathol (2008)

[37]

Gilks "A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary" Am J Surg Pathol (2009) 10.1097/pas.0b013e3181788546

[38]

Helleman "Ovarian cancer cell line panel (OCCP): clinical importance ofmorphological subtypes" PLoS One (2014) 10.1371/journal.pone.0103988

[39]

Dafou "In vitro three-dimensional modelling of human ovarian surface epithelial cells" Cell Prolif (2009) 10.1111/j.1365-2184.2009.00604.x

[40]

Hung "Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome" Clin Cancer Res (2008) 10.1158/1078-0432.ccr-08-0196

[41]

Thiery "Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients" EMBO Mol Med (2014) 10.15252/emmm.201404208

[42]

Westerheide "Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses" PLoS One (2017) 10.1371/journal.pone.0182930

[43]

Smyth "Characterization and properties of nine human ovarian adenocarcinoma cell lines" Cancer Res (1988)

[44]

Brenton "Optimized p53 immunohistochemistry is an accurate predictor ofTP53mutation in ovarian carcinoma" J Pathol Clin Res (2016) 10.1002/cjp2.53

[45]

Marsh "Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing" Sci Rep (2016) 10.1038/srep26191

Metrics

27

Citations

45

References

Details

Published: Apr 24, 2018
Vol/Issue: 9(31)
Pages: 21893-21903

Authors

V

Victoria Heredia-Soto

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Instituto de Salud Carlos III, Madrid 28029, Spain

A

Andrés Redondo

Department of Medical Oncology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Translational Oncology Research Lab, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; School of Medicine, Universidad Autónoma de Madrid, UAM, Madrid 28029, Spain

A

Alberto Berjón

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Department of Pathology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

M

María Miguel-Martín

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

E

Esther Díaz

Translational Oncology Research Lab, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

R

Roberto Crespo

Translational Oncology Research Lab, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

A

Alicia Hernandez

Department of Gynecology and Obstetrics, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

L

Laura Yebenes

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Department of Pathology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

A

Alejandro Gallego

Department of Medical Oncology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

J

Jaime Feliu

Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Instituto de Salud Carlos III, Madrid 28029, Spain; Department of Medical Oncology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Translational Oncology Research Lab, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; School of Medicine, Universidad Autónoma de Madrid, UAM, Madrid 28029, Spain; Cátedra UAM-AMGEN, Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid 28049, Spain

D

David Hardisson

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; School of Medicine, Universidad Autónoma de Madrid, UAM, Madrid 28029, Spain; Department of Pathology, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Molecular Pathology Section, Instituto de Genética Molecular y Médica, INGEMM, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

M

Marta Mendiola

Molecular Pathology and Therapeutic Targets Research Lab, Instituto de Investigación del Hospital Universitario La Paz, IdiPAZ, Hospital Universitario La Paz, HULP, Madrid 28046, Spain; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Instituto de Salud Carlos III, Madrid 28029, Spain; Molecular Pathology Section, Instituto de Genética Molecular y Médica, INGEMM, Hospital Universitario La Paz, HULP, Madrid 28046, Spain

Cite This Article

Victoria Heredia-Soto, Andrés Redondo, Alberto Berjón, et al. (2018). High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget, 9(31), 21893-21903. https://doi.org/10.18632/oncotarget.25098

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

You May Also Like